
Broadening the Conversation About Drug Pricing
The New York Times editorial board recently observed: “We shouldn’t be surprised by any biotech’s failure. We should expect it. Biotechs by their nature offer the promise of disruptive breakthroughs and discoveries, but they’re mostly all-in propositions, based on one molecule or one test. Fail in a Phase III clinical trial — and a majority do — […]